BioPharma Dive March 25, 2025
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a).
Dive Brief:
- Merck & Co. has entered a competitive race for a new type of heart drug, announcing Tuesday it will pay China-based Jiangsu Hengrui Pharmaceuticals $200 million upfront to license a pill that blocks a protein particle believed to contribute to blood vessel blockages.
- Per deal terms, Merck will receive rights outside of the greater China region to the therapy, dubbed HRS-5346 and is currently in Phase 2 testing. Jiangsu Hengrui could receive another $1.77 billion in additional payments, as well as sales royalties, if the drug hits certain development, regulatory and commercial...
Today's Sponsors
Today's Sponsor